​

Exicure Stock (NASDAQ:XCUR)

ForecastOwnershipFinancialsChart
Exicure by TradingView

Previous Close

$1.31

52W Range

$1.05 - $9.48

50D Avg

$1.49

200D Avg

$3.47

Market Cap

$8.48M

Avg Vol (3M)

$421.61K

Beta

3.62

Div Yield

-

XCUR Company Profile

Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

1

IPO Date

May 22, 2018

Website

XCUR Performance

XCUR Financial Summary

Dec 25Dec 24Dec 23
Revenue-$500.00K-
Operating Income-$-12.23M$-15.00M
Net Income$-4.95M$-9.70M$-16.91M
EBITDA-$-8.85M$-15.54M
Basic EPS$-0.79$-1.59$-2.11
Diluted EPS$-0.79$-1.59$-2.11

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
RLYBRallybio Corporation
IBIOiBio, Inc.
CLGNCollPlant Biotechnologies Ltd.
MTVAMetaVia Inc.
CVKDCadrenal Therapeutics, Inc. Common Stock
NRSNNeuroSense Therapeutics Ltd.
TAOXTAO Synergies Inc.
KLTOKlotho Neurosciences, Inc.
SONNSonnet BioTherapeutics Holdings, Inc.